Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Aktiespararna's Aktiedagen Stockholm 2021
27 slides from Expres2ion Biotech Holding Ab's conference presentation, Dec 2, 2021
Slide 1: Proteins for Life
Proteins for Life Aktiespararna’s Aktiedagen Stockholm, December 2, 2021 Bent U. Frandsen, CEO
Slide 2: Forward-looking statements and disclaimer
Forward-looking statements and disclaimer This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this pre
Slide 3: Investment Highlights
Investment Highlights Key player in advanced protein sciences with novel pipeline addressing 45B EUR markets Leader in production of complex proteins with the advantageous ExpreS2 technology Co-Founder of AdaptVac ApS, owner of a unique Virus Like Particle (VLP) technology Pipeline of therapeutics/v
Slide 4: Deep Pipeline for Value Creation
Deep Pipeline for Value Creation Development Progress DISEASE Project/Target Discovery Pre-clinical cGMP / Tox Phase 1 Phase 2 Phase 3 Market Partner/Funding Pharmacology Potential > 30 Coronavirus ABNCoV2/SARS-CoV-2cVLP ABNCoV2/SARS-CoV-2 cVLP I / II I/IIa BN: II billion EUR PREVENT-nCoV > 10 100%
Slide 5: Our Programs
Our Programs Proteins for Life
Slide 6: The 2nd Generation COVID-19 Vaccine
CORONAVIRUS nd The 2 Generation COVID-19 Vaccine With over 5 million deaths worldwide, significant needs remain in the global long-term fight against the SARS-CoV-2 virus: Uncertain duration of effect with current vaccines, expected to need repeated boosters Storage and handling requirements for man
Slide 7: The 2nd Generation COVID-19 Vaccine II
CORONAVIRUS nd The 2 Generation COVID-19 Vaccine II Will the B.1.1.529 Omicron variant replace Delta? Proteins for Life |7 Source: CoVariants.org and GSAID – Last Updated 30 November 2021, 21.00 CET
Slide 8: The Best COVID-19 Vaccine
CORONAVIRUS The Best COVID-19 Vaccine PREVENT-nCoV ABNCoV2 has demonstrated superior preclinical proof-of-concept, and now promising human data Encouraging early findings: Phase I/II Study headline results: Virus • Durable immune response with • 45 humans dosed (6-70µg) Spike proteins on surface sin
Slide 9: ABNCoV2 COVID-19 Vaccine Update (I)
CORONAVIRUS ABNCoV2 COVID-19 Vaccine Update (I) Update on Phase I/IIa trial confirms safety and tolerability and excellent efficacy profile ABNCoV2 induces high neutralisation titers Strong cross neutralization of variants • Dose response: increased titers with higher vaccine doses up to 25 mg, • No
Slide 10: ABNCoV2 COVID-19 Vaccine Update (II)
CORONAVIRUS ABNCoV2 COVID-19 Vaccine Update (II) Bavarian Nordic carries on with the Phase II trial, and granted 800 MDKK funding for Phase III Proteins for Life | 10
Slide 11: COVID-19 License and JV Economics
CORONAVIRUS COVID-19 License and JV Economics ABNCoV2 is already out-licensed with near-term revenue streams supporting ExpreS2ion AdaptVac’s Economics ExpreS2ion’s Economics Paid by Bavarian Nordic Paid by AdaptVac • 4 MEUR upfront (paid in July 2020) • 34% ownership of AdaptVac • Up to 136 MEUR in
Slide 12: COVID-19 Value to ExpreS2ion
CORONAVIRUS 2 COVID-19 Value to ExpreS ion Institutional analysts have higher sales and approval assumptions Estimated COVID-19 + AdaptVac value1 2,800 Danske Bank Carnegie 2,500 Pareto: SEK 68 target COVID-19 + AdaptVac value: SEK 1,322 mn (60.9% of company valuation) Institutional 2,200 SEK millio
Slide 13: HER2+ Breast Cancer Overview
BREAST CANCER HER2+ Breast Cancer Overview The ES2B-C001 vaccine can offer significant benefits compared to current treatment options Over 180,000 people diagnosed with HER2+ breast Monoclonal antibodies are the cornerstone of treatment cancer per year across US, EU, & Japan1,2 for HER2+ breast canc
Slide 14: ES2B-C001 overcomes Herceptin resistance
BREAST CANCER ES2B-C001 overcomes Herceptin resistance The soft agar human cancer cell growth inhibition assay provides in vitro evidence UNTREATED ES2B-C001 Trastuzumab- sensitive HER2+ human cancer Both Herceptin (trastuzumab) and cells1 ES2B-C001 inhibited growth in the trastuzumab-sensitive cell
Slide 15: Strong Preclinical Data for VLP Approach
BREAST CANCER Strong Preclinical Data for VLP Approach ES2B-C001 has demonstrated animal proof-of-concept, and on track to repeat in vivo PoC • Prevention of 50-100% of spontaneous mammary carcinogenesis Preventive studies (mice with pre-disposition to spontaneous development of • Strong tumor growt
Slide 16: Influenza / Malaria Vaccines Update
INFLUENZA / MALARIA Influenza / Malaria Vaccines Update Progression catching up again, after initial delay due to the COVID-19 pandemic Influenza Vaccine Malaria Vaccine >4 billion EUR >0.4 billion EUR The INDIGO consortium 5 vaccines candidates under development that target • Led by University of A
Slide 17: Financials and Outlook
Financials and Outlook Proteins for Life
Slide 18: Financials – Fitting the New Strategy
Financials – Fitting the New Strategy Revenues, SEK ‘000s Operating costs, SEK ‘000s Cash balance, SEK million 6.000 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 160 0 142 5.000 140 -3.000 4.000 120 107 108 3.000 -6.000 100 83 2.000 80 -9.000 1.000 60 -12.000 0 40 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21
Slide 19: Shareholder Composition
Shareholder Composition During 2021 No. of shareholders grows from ~6,000 to ~14,000 No. of shareholders No. of shares outstanding 16.000 35.000.000 14.000 30.000.000 12.000 25.000.000 10.000 20.000.000 8.000 15.000.000 6.000 10.000.000 4.000 2.000 5.000.000 0 0 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q
Slide 20: 2021 – 2023 Outlook
2021 – 2023 Outlook On track to deliver shareholder value 2021 2022 2023 CORONAVIRUS (ABNCoV2) Phase I/II trial, COUGH-1 COUGH-1 BN Phase II BN Phase II BN Phase III BN Phase III BN ready for COUGH-1 initial safety full safety trial trial readout trial initial market launch initiated results (Q2) &
Slide 21: Thank you!
Thank you! Contact: info@expreS2ionbio.com Proteins for Life
Slide 22: Our Technology
Our Technology Proteins for Life
Slide 23: ExpreS2 Platform for Complex Proteins
2 ExpreS Platform for Complex Proteins Enables unique non-viral approach to protein and vaccine production Transfection of desired gene into S2 cells, including secretion signal: 1 week Reducing risks in discovery manufacturing Cell line derived from Drosophila melanogaster ✓ Fast & high level prote
Slide 24: Virus Like Particle (VLP) Technology
Virus Like Particle (VLP) Technology VLP technology has proven track record in cancer vaccine applications (HPV) Our ExpreS2 platform produces the High immunogenic potential complex surface proteins (antigens), • Full length proteins: Exceptionally strong which are critical to immune system attachme
Slide 25: Board and Management
Board and Management Proteins for Life
Slide 26: Board of Directors
Board of Directors Expanded the Board in 2021 in support of the transition to a pipeline-focused business Re- Elected Dr. Martin Roland Jensen, Chairman elected Dr. Karin Garre, Board Member in 2021 • PhD. in Molecular and Cell Biology, Univ. of Copenhagen, Denmark • MD, from University of Copenhage
Slide 27: Management Team
Management Team Expanded team in 2021 brings skills to build our pipeline-focused business Started Bent U. Frandsen, CEO Dr. Mette Thorn, VP Preclinical Development in 2021 • MSc. In Finance/Strategic Management, Copenhagen Business School, • PhD in Immunology, and a MSc in Chem Eng., Tech. Univ of
ExpreS2ion Biotech Holding — Aktiespararna's Aktiedagen Stockholm 2021 on 6ix